The Vetr crowd on Monday upgraded its rating on Celgene Corporation (NASDAQ:CELG) from 3 stars (Buy) issued 16 days ago, to 5 stars (Strong Buy). Crowd sentiment at the time of the upgrade was unanimously positive, with 100 percent of Vetr user ratings bullish.
Vetr's upgrade comes on the heels of biotech's announcement that it would be discontinuing trials of its crohn's disease drug treatment. Following the news, analysts with Baird and Piper Jaffray downgraded the stock while a slew of others, including analysts with UBS and Barclays, lowered their outlook on the company.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average price target on Celgene is up at $144.39, which is above the average analyst price target of $140.50. Less than 2 percent of Vetr users are holding CELG in their watch-lists.